Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Brazil regulator says adolescent death unrelated to Pfizer shot

09/22/2021 | 07:19pm EDT

BRASILIA, Sept 22 (Reuters) - The death of a 16-year-old who had a first dose of the Pfizer/BioNTech vaccine against COVID-19 was due to a prior blood clot condition not related to the vaccine, Brazil's health regulator Anvisa said on Wednesday.

Concluding an investigation into the death earlier this month, Anvisa said it was caused by an auto-immune disease suffered by the adolescent. The Pfizer vaccine is the only one approved for minors in Brazil. "It was a characteristic clinical picture of thrombotic thrombocytopenic purpura, an autoimmune disease," the regulator said in a statement.

Thrombotic thrombocytopenic purpura is a rare disorder that causes blood clots to form in small blood vessels throughout the body that can cause serious medical problems if they restrict blood flow to organs such as the brain, kidneys or heart.

Concerns over COVID-19 vaccines and blood clots has prompted investigations by researchers across the world.

The European Commission requested scientific opinion from the European Medicines Agency (EMA) on whether women and young adults were at higher risk of blood clots after vaccination with AstraZeneca's COVID-19 shot. The EMA could not confirm if this was the case.

Brazil's federal government last week sough to halt COVID-19 vaccinations for adolescents while the death was under investigation as a suspected adverse event, but several state governments vowed to press on.

Some 3.5 million Brazilians between the ages of 12 and 17 have already been immunized.

(Reporting by Anthony Boadle Editing by Sonya Hepinstall and Aurora Ellis)


ę Reuters 2021
All news about ASTRAZENECA PLC
12:41aVACCINATED BUT STUCK : Indians await WHO nod for homegrown shot to travel abroad
RE
10/26ASTRAZENECA : Deutsche Bank reiterates its Buy rating
MD
10/26VACCINATED BUT STUCK : Indians await WHO nod for homegrown shot to travel abroad
RE
10/25AstraZeneca PLC Announces Positive High-Level Results from the TOPAZ-1 Phase III Trial
CI
10/25ASTRAZENECA : Daiichi Sankyo in Clinical Trial Collaboration to Evaluate Datopotamab Derux..
MT
10/25WALL STREET STOCK EXCHANGE : 84% of Q3 earnings reports exceed expectations
10/25ANALYST RECOMMENDATIONS : American Express, Beyond Meat, Microsoft, Oracle, Weibo...
10/25UNIVERSITY OF BIRMINGHAM : A third of leukaemia patients do not generate any antibody resp..
AQ
10/25ASTRAZENECA : Imfinzi plus chemotherapy significantly improved overall survival in 1st-lin..
AQ
10/25ASTRAZENECA : JP Morgan reiterates its Buy rating
MD
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 441 M - -
Net income 2021 4 862 M - -
Net Debt 2021 24 715 M - -
P/E ratio 2021 35,9x
Yield 2021 2,27%
Capitalization 192 B 192 B -
EV / Sales 2021 6,11x
EV / Sales 2022 4,95x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 123,93 $
Average target price 137,83 $
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC22.92%192 243
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231